m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05703
 [1]
m6A modification miR-1908-5p miR-1908-5p METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-1908-5p HOPX  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target hsa-miR-1908-5p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-1908-5p microRNA View Details
Regulated Target HOP homeobox (HOPX) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3-mediated m6A modification of hsa-miR-1908-5p contributes to nasopharyngeal carcinoma progression by targeting HOP homeobox (HOPX).
Responsed Disease Nasopharyngeal carcinoma ICD-11: 2B6B
 Disease Info 
Cell Process Cell migration
In-vitro Model
NP69SV40T
 N.A. Homo sapiens CVCL_F755
C666-1 Nasopharyngeal carcinoma Homo sapiens CVCL_7949
In-vivo Model Male BALB/c-nude mice (5-week-old) were used in this study. First, the Antigo miR-1908-5p (Antigo-miR) for knocking down miR-1908-5p as well as its negative control (Antigo-NC) were acquired from GenePharma (China). Antigo-miR and Antigo-NC were each introduced into C666-1 cells which were then delivered through the tail of every mouse (n = 3 per group). Thereafter, all mice were raised well, and the long diameter and short diameter of tumors were measured every week. The tumor volume was calculated as tumor volume (mm3) = (short diameter)2 × long diameter/2. After 5 weeks, the mice were euthanized, and their tumors were weighed. All animal protocols were followed in accordance with the Institutional Animal Care and Use Committee of our hospital.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B6B: Nasopharyngeal carcinoma 20 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Lotilaner Approved [2]
External Link
TTD: DV87CQ
 Compound Name Toripalimab Approved in China [3]
External Link
TTD: D92OCI
 Compound Name Tabelecleucel Phase 2 [4]
Synonyms
Tab-cel
    Click to Show/Hide
External Link
TTD: DY4Q6M
 Compound Name A167 Phase 3 [5]
Synonyms
KL-A167
    Click to Show/Hide
External Link
TTD: DI89WD
 Compound Name MLN4924 Phase 1 [6]
Synonyms
Pevonedistat; 905579-51-3; MLN-4924; MLN 4924; UNII-S3AZD8D215; S3AZD8D215; Sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-2-hydroxycyclopentyl]methyl ester; ((1S,2S,4R)-4-(4-(((S)-2,3-dihydro-1H-inden-1-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate; C21H25N5O4S; [(1s,2s,4r)-4-{4-[(1s)-2,3-Dihydro-1h-Inden-1-Ylamino]-7h-Pyrrolo[2,3-D]pyrimidin-7-Yl}-2-Hydroxycyclopentyl]methyl Sulfamate; Pevonedistat [USAN:INN]; 3gzn
    Click to Show/Hide
External Link
CID: 16720766
TTD: D0ZD2M
DrugBank: DB11759
 Compound Name TT10 Phase 3 [7]
Synonyms
EBVST; GVYPHJQPOHDZEI-UHFFFAOYSA-N; TT-10; 2230640-94-3
    Click to Show/Hide
External Link
CID: 134827875
TTD: D0NS3O
 Compound Name DE-766 Phase 3 [8]
External Link
TTD: D0FJ1W
 Compound Name Avastin+/-Tarceva Phase 3 [9]
Synonyms
Juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; Regianin; Juglon; Nucin; 5-Hydroxynaphthalene-1,4-dione; Walnut extract; 5-Hydroxynaphthoquinone; Akhnot; Yuglon; 8-Hydroxy-1,4-naphthoquinone; CI Natural Brown 7; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; 1,4-Naphthoquinone, 5-hydroxy-; CI 75500; Juglane; Jugnlon; Iuglon; Caswell No 515AA; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; UNII-W6Q80SK9L6; NSC 622948; NSC 153189; CCRIS
    Click to Show/Hide
External Link
CID: 3806
TTD: D0C0NH
 Compound Name MK-2206 Phase 2 [10]
Synonyms
1032349-93-1; UNII-51HZG6MP1K; MK 2206; 51HZG6MP1K; CHEMBL1079175; CHEBI:67271; NCGC00186465-01; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one; DSSTox_RID_83143; DSSTox_CID_28874; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; DSSTox_GSID_48948; 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one; 1,2,4-Triazolo[3,4-f][1,6]naphthyridin-3(2H)-one, 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-;
    Click to Show/Hide
External Link
CID: 24964624
TTD: D0W3RW
 Compound Name R-roscovitine Phase 2 [11]
Synonyms
Seliciclib; roscovitine; 186692-46-6; (R)-roscovitine; CYC202; CYC-202; CYC 202; 2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine; UNII-0ES1C2KQ94; Roscovitine (Seliciclib,CYC202); NSC 701554; AL-39256; CHEMBL14762; 0ES1C2KQ94; CHEBI:45307; NSC701554; NSC-701554; (2R)-2-[[6-(benzylamino)-9-isopropyl-purin-2-yl]amino]butan-1-ol; (R)-2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol; (2R)-2-[[6-(benzylamino)-9-propan-2-ylpurin-2-yl]amino]butan-1-ol; RRC; Rosco; M02443; BMK1-E12; CYC202, Seliciclib, R-roscovitine, Roscovitine; (2r)-2-{[6-(benzylamino)-9-isopropyl-9h-purin-2-yl]amino}-1-butanol; 2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol; 2-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-(R)-1-butanol; 6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine
    Click to Show/Hide
External Link
CID: 160355
TTD: D05ADP
DrugBank: DB06195
 Compound Name Epstein-barr virus-specific immunotherapy Phase 2 [12]
Synonyms
Epstein-barr virus-specific immunotherapy (nasopharyngeal carcinoma)
    Click to Show/Hide
External Link
TTD: D03XEY
 Compound Name LMP1-CAR-T cells Phase 1/2 [13]
External Link
TTD: D0RJ2V
 Compound Name APG-1387 Phase 1 [14]
Synonyms
AKLBERUGKZNEJY-RTEPGWBGSA-N; SCHEMBL15490706
    Click to Show/Hide
External Link
CID: 73336238
TTD: D0NP8P
 Compound Name GSK618334 Phase 1 [15]
Synonyms
Fingolimod hydrochloride; 162359-56-0; FTY720; Fingolimod HCl; Gilenya; Gilenia; Fty-720; Fty 720; Fingolimod (FTY720) HCl; Fingolimod (hydrochloride); 2-Amino-2-(4-octylphenethyl)propane-1,3-diol hydrochloride; 2-Amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride; UNII-G926EC510T; Fingolimod hydrochloride [USAN]; CHEBI:63112; G926EC510T; 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride; AK-33554; 2-AMINO-2-[2-(4-OCTYL-PHENYL)-ETHYL]-PROPANE-1,3-DIOL HCL; Fingolimod-d4 Hydrochloride
    Click to Show/Hide
External Link
CID: 107969
TTD: D0HI1K
 Compound Name PD173074 Investigative [16]
External Link
CID: 1401
TTD: D0VF6E
 Compound Name Ad5f35-LMPd1-2-transduced autologous dendritic cells Investigative [17]
Synonyms
AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI
    Click to Show/Hide
External Link
TTD: D0Q8PF
 Compound Name THZ1 Investigative [18]
Synonyms
HY-80013
    Click to Show/Hide
External Link
CID: 73602827
TTD: D0LO5B
 Compound Name SAIT301 Investigative [8]
External Link
TTD: D07QNH
 Compound Name HITOPK-032 Investigative [19]
Synonyms
HI-TOPK-32; HI-TOPK-032; C20H11N5OS; N-(12-cyanoindolizino[2,3-b]quinoxalin-2-yl)thiophene-2-carboxamide; 799819-78-6; N-(12-cyano-2-indolizino[2,3-b]quinoxalinyl)-2-thiophenecarboxamide; AC1LYXW6; HI-TOPC-032; SCHEMBL15270774; DTXSID00365681; AOB1064; SYN5181; MolPort-002-572-638; ACN-S001950; ZINC2320807; STK548195; AKOS005476059; CS-6900; MCULE-6063579279; ACN-001741; AS-16541; HY-101550; B5640; J3.626.778J
    Click to Show/Hide
External Link
CID: 1936439
TTD: D06DPJ
 Compound Name Ro5203280 Investigative [20]
Synonyms
Ro3280; Ro 3280; PharmaGSID_48511; 4-((9-Cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide; DJNZZLZKAXGMMC-UHFFFAOYSA-N; 79C; DSSTox_RID_82762; DSSTox_CID_28485; DSSTox_GSID_48511; SCHEMBL1559146; GTPL9403; DTXSID4048511; AOB5394
    Click to Show/Hide
External Link
CID: 25015677
TTD: D05WDM
References
Ref 1 Methyltransferase-like 3-mediated m6A modification of miR-1908-5p contributes to nasopharyngeal carcinoma progression by targeting homeodomain-only protein homeobox. Environ Toxicol. 2024 Mar;39(3):1631-1640. doi: 10.1002/tox.24032. Epub 2023 Nov 29.
Ref 2 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217603
Ref 3 Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
Ref 4 ClinicalTrials.gov (NCT00953420) Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN). U.S. National Institutes of Health.
Ref 5 ClinicalTrials.gov (NCT05294172) KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial. U.S.National Institutes of Health.
Ref 6 Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Cell Death Dis. 2017 Jun 1;8(6):e2834.
Ref 7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 8 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
Ref 9 Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.PLoS One. 2016 Jun 3;11(6):e0156833.
Ref 10 UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72.
Ref 11 Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24.
Ref 12 ClinicalTrials.gov (NCT00834093) A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma. U.S. National Institutes of Health.
Ref 13 ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application
Ref 14 XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510.
Ref 15 Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma. Oncotarget. 2016 Dec 6;7(49):80586-80598. doi: 10.18632/oncotarget.13014.
Ref 16 Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.Cancer Biol Ther. 2014;15(12):1613-21.
Ref 17 CA patent application no. 876139, Nanotherapeutics for drug targeting.
Ref 18 Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma.Cancer Res. 2017 Dec 1;77(23):6614-6626.
Ref 19 PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.Oncotarget. 2016 May 3;7(18):26604-16.
Ref 20 Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.